Our Science
We leverage expertise in human genetics, data science, immunology, and neurology to gain a deeper understanding to the biologic mechanisms and etiology of the diseases we aim to treat and to prioritize the targets within our portfolio.
![](https://neuron23.com/wp-content/uploads/2022/04/eyecatch.jpg)
New Breakthroughs
Require New Methods
We leverage our strengths in chemistry, genetic target selection and validation, and AI-enabled drug discovery to uncover promising new ways to fight disease.
Target | Therapeutic Area | Discovery | Preclinical | Phase 1 | Phase 2 |
---|---|---|---|---|---|
LRRK2 | Parkinson’s Disease | ||||
Systemic TYK2 | Systemic Inflammation | ||||
Central TYK2 | Neuroinflammation, MS | ||||
Target 4 | Not disclosed | ||||
Target 5 | Not disclosed |
This is Just the Beginning
We leverage our strengths in chemistry, genetic target selection and validation, and AI-enabled drug discovery to uncover promising new ways to fight disease.
Neuron23 Series A
Amount raised:
$13M from Kleiner Perkins
Amount raised:
$20.5M from Westlake and Kleiner Perkins
Amount raised:
$80M from Redmile, Cowen, Acorn, Surveyor-Citadel, HBM, Perceptive, Westlake, and Kleiner Perkins
Amount raised:
$100M from SoftBank, Chimera, Redmile Group, Westlake Biopartners, and Kleiner Perkins Caufield and Byers, Cowen Healthcare Investments, Acorn, Surveyor-Citadel, Perceptive Advisors and HBM